Initially, this trial had two separate cohorts; in cohort 1, patients were enrolled according to their ER+/HER2- biomarker status alone, whereas in cohort 2 they were also required to have cancers with cyclin D1 amplification, p16 loss, or both. Here, CCND1 is linked to cancer.